

## Refine Search

### Search Results -

Terms	Documents
L12 and addiction	58

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L14

Refine Search

Recall Text

Clear

Interrupt

### Search History

DATE: Thursday, August 26, 2004    [Printable Copy](#)    [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>			
<u>L14</u>	L12 and addiction	58	<u>L14</u>
<u>L13</u>	L12 and addiction	0	<u>L13</u>
<u>L12</u>	L11 and alcoholism	86	<u>L12</u>
<u>L11</u>	L10 and withdrawal	258	<u>L11</u>
<u>L10</u>	l1 or l6	1252	<u>L10</u>
<u>L9</u>	L6 same alcoholism	2	<u>L9</u>
<u>L8</u>	L6 and alcoholism	84	<u>L8</u>
<u>L7</u>	L6 and alcholism	1	<u>L7</u>
<u>L6</u>	GABA adj agonist	398	<u>L6</u>
<u>L5</u>	L1 and (alcoholism)	101	<u>L5</u>
<u>L4</u>	L1 same (alcohol\$)	28	<u>L4</u>
<u>L3</u>	L1 same (addiction)	9	<u>L3</u>
<u>L2</u>	L1 same (alcoholism)	8	<u>L2</u>
<u>L1</u>	baclophen or baclofen	946	<u>L1</u>

[First Hit](#)      [Previous Doc](#)      [Next Doc](#)      [Go to Doc#](#)☐ [Generate Collection](#) [Print](#)

L5: Entry 25 of 28

File: JPAB

Oct 20, 1988

PUB-NO: JP363253022A

DOCUMENT-IDENTIFIER: JP 63253022 A

TITLE: BACLOFEN PHARMACEUTICAL FOR EXTERNAL USE

PUBN-DATE: October 20, 1988

## INVENTOR-INFORMATION:

NAME

COUNTRY

WATANABE, SHIGEYUKI

SATO, SUSUMU

## ASSIGNEE-INFORMATION:

NAME

COUNTRY

NITTO ELECTRIC IND CO LTD

APPL-NO: JP62086354

APPL-DATE: April 8, 1987

INT-CL (IPC): A61K 31/195; A61K 31/195; A61K 47/00; A61K 47/00


## ABSTRACT:

PURPOSE: To obtain a pharmaceutical for external use, containing baclofen, as necessary, with a percutaneous absorption adjuvant or cyclodextrin and capable of exhibiting sustained drug effects without side effects on digestive systems, hallucination, dependence, etc.

CONSTITUTION: A pharmaceutical obtained by containing  $\beta$ -(aminomethyl)-p-chlorohydrocinnamic acid (baclofen) expressed by the formula, as necessary, with a percutaneous absorption adjuvant, e.g. 6~12C alcohol and organic solvent (e.g. lower alcohol or propylene glycol) or cyclodextrin in a base, such as ointment base, solvent or tacky agent. Water-solubility of the baclofen is improved by blending the cyclodextrin and percutaneous absorbability is improved without depositing crystals.

COPYRIGHT: (C)1988, JPO&amp;Japio

[Previous Doc](#)      [Next Doc](#)      [Go to Doc#](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bo  
Search PubMed for Go Clear  
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Drug Alcohol Depend. 1993 Sep;33(2):157-63.

[Related Articles, Links](#)

#### Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

#### PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

#### Related Resources

Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

### Baclofen administration for the treatment of affective disorders in alcoholic patients.

Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko AJ, Borodkin YuS.

Leningrad Regional Dispensary of Narcology, Russia.

Ninety alcoholic patients with the secondary affective disorders (anxiety, depression) were divided into four groups. Patients in the first group received GABAB receptor ligands (baclofen), those in the second group, diazepam, those in the third group, amitriptyline and those in the fourth group, placebo. The results of clinical, psychological (tests of Spielberger, Zung and MMPI), and electrophysiological (superslow omega-potential) investigations showed that baclofen is an effective drug for affective disturbances in alcoholic patients, with efficacy superior to placebo and equal to diazepam and amitriptyline. At the same time baclofen does not have the side-effects and complications of the latter. Significant changes in platelet MAOB activity and the dopamine, serotonin and GABA concentrations in blood after treatment were not found in the four patient groups. The peripheral metabolism of GABA and monoamines do not seem to be related to the development of secondary affective disorders in alcoholic patients. This investigation encourages the search for drugs acting on the affective psychopathology of GABAB receptor ligands.


#### Publication Types:

- Clinical Trial
- Randomized Controlled Trial

PMID: 8261880 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bo  
Search PubMed for [ ] Go Clear  
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Alcohol Clin Exp Res. 2000 Jan;24(1):58-66.

[Related Articles, Links](#)

Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources

Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

## Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.

Colombo G, Agabio R, Carai MA, Lobina C, Pani M, Reali R, Addolorato G, Gessa GL.


CNR Center for Neuropharmacology, Bernard B. Brodie Department of Neuroscience, University of Cagliari, Italy. colomb@unica.it

**BACKGROUND:** The similarities between the pharmacological effects of the gamma-aminobutyric acid receptor agonist, baclofen, and the alcohol-substituting agent, gamma-hydroxybutyric acid, led us to investigate whether baclofen was capable of reducing (a) ethanol withdrawal syndrome in ethanol-dependent rats and (b) voluntary ethanol intake in ethanol-preferring rats. **METHODS:** In experiment 1, Wistar rats were rendered physically dependent on ethanol by the repeated administration of intoxicating doses of ethanol for 6 consecutive days. Baclofen was acutely administered intraperitoneally at doses of 10, 20, and 40 mg/kg. In experiment 2, baclofen (0, 2.5, 5, and 10 mg/kg, intraperitoneally) was administered once a day for 14 consecutive days to ethanol-preferring sP rats that had continuous access to ethanol (10%, v/v) and water under the two-bottle free choice regimen. **RESULTS:** In experiment 1, baclofen dose-dependently decreased the intensity of ethanol withdrawal signs; furthermore, 20 mg/kg of baclofen protected from audiogenic seizures in ethanol-withdrawn rats. In experiment 2, baclofen selectively and dose-dependently reduced voluntary ethanol intake; a compensatory increase in water intake left total fluid intake virtually unchanged. **CONCLUSIONS:** These results are in close agreement with those of a preliminary clinical study and suggest that baclofen may constitute a novel therapeutic agent for alcoholism.

PMID: 10656194 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bo  
Search PubMed for baclophen + addiction + ethanol Go Clear  
Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 20 Sort Send to Text

Text Version

Items 1-3 of 3

One page.

#### Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

#### PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

#### Related Resources

Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

☐ 1: [Broadbent J, Harless WE.](#)

[Related Articles, Links](#)



Differential effects of GABA(A) and GABA(B) agonists on sensitization to the locomotor stimulant effects of ethanol in DBA/2 J mice.

Psychopharmacology (Berl). 1999 Jan;141(2):197-205.

PMID: 9952045 [PubMed - indexed for MEDLINE]

☐ 2: [Wrona MZ, Waskiewicz J, Han QP, Han J, Li H, Dryhurst G.](#)

[Related Articles, Links](#)



Putative oxidative metabolites of 1-methyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline of potential relevance to the addictive and neurodegenerative consequences of ethanol abuse.

Alcohol. 1997 May-Jun;14(3):213-23.

PMID: 9160798 [PubMed - indexed for MEDLINE]

☐ 3: [Gold MS, Dackis CA, Washton AM.](#)

[Related Articles, Links](#)



The sequential use of clonidine and naltrexone in the treatment of opiate addicts.

Adv Alcohol Subst Abuse. 1984 Spring;3(3):19-39. Review.

PMID: 6388273 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bo  
Search PubMed for [ ] Go Clear  
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Alcohol. 1999 Apr;17(3):231-40.

Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central


ALCOHOL SCIENCE  
FULL-TEXT ARTICLE

## The effects of the GABA(B) agonist baclofen on the temporal and structural characteristics of ethanol intake.

Smith BR, Boyle AE, Amit Z.

Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, Quebec, Canada. smith@csbn.concordia.ca

The present study examined the behavioral processes mediating the influence of the GABA(B) agonist baclofen on the maintenance of voluntary ethanol intake. Long-Evans rats were randomly assigned to two groups, one receiving baclofen (10 mg/kg, IP) and the other an equal volume of saline. Subjects were presented with a free choice of ethanol (10% v/v) and water immediately following drug injections, which occurred every other day. The results demonstrated that baclofen treatment resulted in an overall increase in the intake of absolute ethanol but failed to influence the intake of water. In contrast, food intake was substantially attenuated as evidenced by a decrease in the number of pellets consumed in subjects treated with baclofen. A microanalysis of the patterns of food and fluid bouts indicated that the enhanced ethanol intake was primarily a function of an increase in the frequency of ethanol bouts. In contrast, the decrease in food intake appeared to be a reflection of a decrease in the size of the food meals but not their frequency. An analysis of the temporal pattern of intake over the 23-h test sessions indicated that baclofen treatment produced a biphasic effect on ethanol intake with a slight decrease in intake during the first hour following treatment. Baclofen-treated animals then were observed to consume greater amounts of ethanol than did saline controls throughout the remainder of the dark cycle as well as into the light cycle. Although ethanol intake gradually decreased in controls throughout the light cycle, baclofen-treated subjects maintained a consistent level of intake throughout this period. Furthermore, there was a clear dissociation between the temporal pattern of ethanol intake and that of food and water, as intake of the latter substances was shown to decrease during the first hour following injection, but unlike with ethanol, no increase in intake was observed during the remainder of the test session. The nature of the effects of baclofen observed in the present study would suggest that the GABA(B) receptor system may not play a central role in the mediation of voluntary ethanol intake.



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bo  
Search PubMed for baclophen + alcoholism Go Clear  
Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 20 Sort Send to Text

Text Version

Items 1-14 of 14

One page.

## Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

## PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

## Related Resources

Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

☐ 1: [Anstrom KK, Cromwell HC, Markowski T, Woodward DJ.](#) Related Articles, Links

Effect of baclofen on alcohol and sucrose self-administration in rats.  
Alcohol Clin Exp Res. 2003 Jun;27(6):900-8.  
PMID: 12824810 [PubMed - indexed for MEDLINE]

☐ 2: [Colombo G, Serra S, Brunetti G, Vacca G, Carai MA, Gessa GL.](#) Related Articles, Links

Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats.  
Drug Alcohol Depend. 2003 May 1;70(1):105-8.  
PMID: 12681531 [PubMed - indexed for MEDLINE]

☐ 3: [Boehm SL 2nd, Piercy MM, Bergstrom HC, Phillips TJ.](#) Related Articles, Links

Ventral tegmental area region governs GABA(B) receptor modulation of ethanol-stimulated activity in mice.  
Neuroscience. 2002;115(1):185-200.  
PMID: 12401333 [PubMed - indexed for MEDLINE]

☐ 4: [Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G.](#) Related Articles, Links

Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study.  
Alcohol Alcohol. 2002 Sep-Oct;37(5):504-8.  
PMID: 12217947 [PubMed - indexed for MEDLINE]

☐ 5: [Vescovi PP, Coiro V.](#) Related Articles, Links

Different control of GH secretion by gamma-amino- and gamma-hydroxy-butyric acid in 4-year abstinent alcoholics.  
Drug Alcohol Depend. 2001 Feb 1;61(3):217-21.  
PMID: 11164685 [PubMed - indexed for MEDLINE]


☐ 6: [Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G.](#) Related Articles, Links

Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence.  
Alcohol Clin Exp Res. 2000 Jan;24(1):67-71.  
PMID: 10656195 [PubMed - indexed for MEDLINE]


☐ 7: [Colombo G, Agabio R, Carai MA, Lobina C, Pani M, Reali R, Addolorato G, Gessa GL.](#) Related Articles, Links

Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.  
Alcohol Clin Exp Res. 2000 Jan;24(1):58-66.  
PMID: 10656194 [PubMed - indexed for MEDLINE]


☐ **8:** [Vescovi PP, Volpi R, Coiro V.](#) [Related Articles](#), [Links](#)

 **Alcoholism abolishes the gamma-aminobutyric acid (GABA)ergic control of GH secretion in humans.**  
Alcohol. 1998 Nov;16(4):325-8.  
PMID: 9818985 [PubMed - indexed for MEDLINE]


☐ **9:** [Wrona MZ, Waskiewicz J, Han QP, Han J, Li H, Dryhurst G.](#) [Related Articles](#), [Links](#)

 **Putative oxidative metabolites of 1-methyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline of potential relevance to the addictive and neurodegenerative consequences of ethanol abuse.**  
Alcohol. 1997 May-Jun;14(3):213-23.  
PMID: 9160798 [PubMed - indexed for MEDLINE]


☐ **10:** [Krupitskii EM, Burakov AM, Grinenko AIa, Borodkin IuS.](#) [Related Articles](#), [Links](#)

 **[Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients]**  
Zh Nevropatol Psikhiatr Im S S Korsakova. 1995;95(6):67-71. Russian.  
PMID: 8788983 [PubMed - indexed for MEDLINE]


☐ **11:** [Krupitskii EM, Burakov AM, Ivanov VB, Karandashova GF, Lapin IP, Grinenko AIa, Borodkin IuS.](#) [Related Articles](#), [Links](#)

 **[The use of baclofen for treating affective disorders in alcoholism]**  
Zh Nevropatol Psikhiatr Im S S Korsakova. 1994;94(1):57-61. Russian.  
PMID: 8009935 [PubMed - indexed for MEDLINE]


☐ **12:** [Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko AJa, Borodkin YuS.](#) [Related Articles](#), [Links](#)

 **Baclofen administration for the treatment of affective disorders in alcoholic patients.**  
Drug Alcohol Depend. 1993 Sep;33(2):157-63.  
PMID: 8261880 [PubMed - indexed for MEDLINE]

☐ **13:** [Tarika JS, Winger G.](#) [Related Articles](#), [Links](#)

 **The effects of ethanol, phenobarbital, and baclofen on ethanol withdrawal in the rhesus monkey.**  
Psychopharmacology (Berl). 1980;70(2):201-8.  
PMID: 6776581 [PubMed - indexed for MEDLINE]

☐ **14:** [Cott J, Carlsson A, Engel J, Lindqvist M.](#) [Related Articles](#), [Links](#)

 **Suppression of ethanol-induced locomotor stimulation by GABA-like drugs.**  
Naunyn Schmiedebergs Arch Pharmacol. 1976 Dec 17;295(3):203-9.  
PMID: 1012342 [PubMed - indexed for MEDLINE]

**Display** **Summary** Show: **20** **Sort** **Send to** **Text**

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37